Globe Newswire

Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued a patent by the European Patent Office protecting its T cell receptor (TCR) targeting NY-ESO-1 (New York esophageal squamous cell carcinoma 1), a well-recognized and validated cancer-testis... (continue reading...)

The company is well in line with the previously presented development plan. Relevant adjustments from previous lab tests have been made, and the company is now fully focused on integrating the driver assistance system BlincVision into vehicles.

Part of the integration work involves evaluating sensor placements, adapting communication interfaces to vehicles and optimizing the system for use in a mobile environment.

Optimizing sensor placements maximizes efficiency and... (continue reading...)

Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued a patent by the European Patent Office protecting its T cell receptor (TCR) targeting NY-ESO-1 (New York esophageal squamous cell carcinoma 1), a well-recognized and validated cancer-testis... (continue reading...)

Summary:

First half-year better than expected at Gabriel Holding A/S as a result of growth in the Group’s global fabric business.

Selected financial highlights and comments:

• The Group achieved growth in its global fabric business in the half-year, in particular in the business units Gabriel Fabrics and SampleMaster. As expected, revenue from the furniture upholstery units (FurnMaster) was lower
• The Group’s total revenue was DKK 469.0 million (DKK... (continue reading...)

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION